https://www.aigom.it/wp-content/uploads/2025/03/2aprile1.png831600Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-03-25 09:40:272025-03-25 09:40:272 APRILE 2025-NUTRIZIONE E ONCOLOGIA: UN DIALOGO TRA RICERCA DI BASE E CLINICA
https://www.aigom.it/wp-content/uploads/2025/03/25.3.png1215960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-03-25 09:16:212025-03-25 09:16:21PHASE II EFFICACY AND SAFETY OF 80 MG OSIMERTINIB IN PATIENTS WITH LEPTOMENINGEAL METASTASES ASSOCIATED WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (BLOSSOM).
https://www.aigom.it/wp-content/uploads/2025/03/IMM18.3.png1136960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-03-18 08:35:452025-03-18 08:35:45OSIMERTINIB AFTER CHEMORADIOTHERAPY IN STAGE III EGFR-MUTATED NSCLC.
https://www.aigom.it/wp-content/uploads/2025/03/LOC.11.3.png1342960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-03-11 08:47:002025-03-11 08:47:00FIRST-LINE NIVOLUMAB PLUS RELATLIMAB VERSUS NIVOLUMAB PLUS IPILIMUMAB IN ADVANCED MELANOMA: AN INDIRECT TREATMENT COMPARISON USING RELATIVITY-047 AND CHECKMATE 067 TRIAL DATA.
https://www.aigom.it/wp-content/uploads/2025/03/loc14-15-3.png706748Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-03-04 09:23:052025-03-17 08:45:32NEGRAR DI VALPOLICELLA (VE)-SCUOLA DI METODOLOGIA DELLA RICERCA CLINICA 2025-11° EDIZIONE VENERDI 14-SABATO 15 MARZO 2025
https://www.aigom.it/wp-content/uploads/2025/03/art4.3.png1242960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-03-04 08:49:132025-03-04 08:58:47FINAL, 10-YEAR OUTCOMES WITH NIVOLUMAB PLUS IPILIMUMAB IN ADVANCED MELANOMA.
